Development of dual PLD1/2 and PLD2 selective inhibitors from a common 1,3,8-triazaspiro[4.5]decane core: Discovery of ML298 and ML299 that decrease invasive migration in U87-MG glioblastoma cells

Journal of Medicinal Chemistry

Volumn 56, Issue 6, 2013, Pages 2695-2699

  O'Reilly, Matthew C ^b   Scott, Sarah A ^a,b   Brown, Kyle A ^a,b   Oguin, Thomas H ^c   Thomas, Paul G ^c   Daniels, J Scott ^a,b   Morrison, Ryan ^a,b   Brown, H Alex ^a,b   Lindsley, Craig W ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY   (United States)

^c ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; DECANE; METHYL GROUP; ML 298; ML 299; PHOSPHODIESTERASE INHIBITOR; PHOSPHOLIPASE D1; PHOSPHOLIPASE D2; UNCLASSIFIED DRUG;

ARTICLE; CELL MIGRATION; CONTROLLED STUDY; GLIOBLASTOMA; HUMAN; HUMAN CELL; IC 50; STRUCTURE ACTIVITY RELATION;

BENZAMIDES; CELL LINE, TUMOR; CELL MOVEMENT; DRUG DISCOVERY; ENZYME INHIBITORS; GLIOBLASTOMA; HUMANS; NEOPLASM INVASIVENESS; PHOSPHOLIPASE D; SPIRO COMPOUNDS;

EID: 84875704159     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm301782e     Document Type: Article

References (18)

1. Selvy, P. E.; Lavieri, R.; Lindsley, C. W.; Brown, H. A. Phospholipase D: enzymology, signaling and chemical modulation Chem. Rev. 2011, 111, 6064-6119
2. Scott, S. A.; Selvy, P. E.; Buck, J. R.; Cho, H. P.; Criswell, T. L.; Thomas, A. L.; Armstrong, M. D.; Arteaga, C. L.; Lindsley, C. W.; Brown, H. A. Design of isoform-selective phospholipase D inhibitors that modulate cancer cell invasiveness Nat. Chem. Biol. 2009, 5, 108-117
3. Brown, H. A.; Henage, L. G.; Preininger, A. M.; Xiang, Y.; Exton, J. H. Biochemical analysis of phospholipase D Methods Enzymol. 2007, 434, 49-87
4. Foster, D. A. Phosphatidic acid signaling to mTOR: signals for the survival of human cancer cells Biochim. Biophys. Acta 2009, 1791, 949-955
5. Noh, D. Y. Overexpression of phospholipase D1 in human breast cancer tissues Cancer Lett. 2000, 161, 207-214
6. Zhao, Y.; Ehara, H.; Akao, Y.; Shamoto, M.; Nakagawa, Y.; Banno, Y.; Deguchi, T.; Ohishi, N.; Yagi, K.; Nozawa, Y. Increased activity and intranuclear expression of phospholipase D2 in human renal cancer Biochem. Biophys. Res. Commun. 2000, 278, 140-143
7. Yamada, Y. Association of a polymorphism of the phospholipase D2 gene with the prevalence of colorectal cancer J. Mol. Med. 2003, 81, 126-131
8. Oliveira, T. G.; Chan, R. B.; Tian, H.; Laredo, M.; Shui, G.; Staniszewski, A.; Zhang, H.; Wang, L.; Kim, T. W.; Duff, K. E.; Wenk, M. R.; Arancio, O.; Di Paolo, G. Phospholipase D2 ablation ameliorates Alzheimer's disease-linked synaptic dysfunction and cognitive deficits J. Neurosci. 2010, 30, 16419-16428
9. Elvers, M.; Stegner, D.; Hagedorn, I.; Kleinschnitz, C.; Braun, A.; Kuijpers, M. E.; Boesl, M.; Chen, Q.; Heemskerk, J. W.; Stoll, G.; Frohman, M. A.; Nieswandt, B. Impaired αIIbβ3 integrin activation and shear-dependent thrombus formation in mice lacking phospholipase D1 Sci. Signaling 2010, 3, 1-10
10. Monovich, L.; Mugrage, B.; Quadros, E.; Toscano, K.; Tommasi, R.; LaVoie, S.; Liu, E.; Du, Z. M.; LaSala, D.; Boyar, W.; Steed, P. Optimization of halopemide for phospholipase D2 inhibition Bioorg. Med. Chem. Lett. 2007, 17, 2310-2311
11. De Cuyper, H.; van Praag, H. M.; Verstraeten, D. The clinical significance of halopemide, a dopamine-blocker related to the butyrophenones Neuropsychobiology 1984, 12, 211-223
12. Lewis, J. A.; Scott, S. A.; Lavieri, R.; Buck, J. R.; Selvy, P. E.; Stoops, S. L.; Armstrong, M. D.; Brown, H. A.; Lindsley, C. W. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part I: Impact of alternative halogenated privileged structures on PLD1 specificity Bioorg. Med. Chem. Lett. 2009, 19, 1916-1919
13. Lavieri, R.; Lewis, J. A.; Scott, S. A.; Selvy, P. E.; Buck, J.; Armstrong, M. D.; Brown, H. A.; Lindsley, C. W. Design and synthesis of isoform-selective phospholipase D (PLD) inhibitors. Part II: PLD2 selectivity by virtue of a triazaspirone privileged structure Bioorg. Med. Chem. Lett. 2009, 19, 2240-2244
14. Lavieri, R.; Scott, S. A.; Selvy, P. E.; Brown, H. A.; Lindsley, C. W. Design, synthesis and biological evaluation of halogenated N -(2-(4-oxo-1-phenyl-1,3,8-triazasprio[4.5]decan-8-yl)ethylbenzamides: discovery of an isoform selective small-molecule phospholipase D2 (PLD2) inhibitor J. Med. Chem. 2010, 53, 6706-6719
15. Wood, M. R.; Hopkins, C. R.; Brogan, J. T.; Conn, P. J.; Lindsley, C. W. "Molecular switches" on allosteric ligands that modulate modes of pharmacology Biochemistry 2011, 50, 2403-2410
16. Conn, P. J.; Christopolous, A.; Lindsley, C. W. Allosteric modulators of GPCRs as a novel approach to treatment of CNS disorders Nat. Rev. Drug Discovery 2009, 8, 41-54
17. For information on the MLPCN, see http://mli.nih.gov/mli.
18. For information on Ricerca, see www.ricerca.com.